Loading...
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
Azacitidine (AZA), the reference treatment for most higher-risk myelodysplastic (MDS) patients can also improve overall survival (OS) in elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy, but reliable biological markers predicting response and OS in patients treated...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5564547/ https://ncbi.nlm.nih.gov/pubmed/28514758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17482 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|